Transforming growth factor‐β signaling and cirrhosis
Jeffrey L. Wrana – 30 December 2003
Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species
Sherryll L. Michael, Neil R. Pumford, Philip R. Mayeux, Michael R. Niesman, Jack A. Hinson – 30 December 2003 – Hepatotoxic doses of acetaminophen to mice produce not only acetaminophen‐protein adducts in the centrilobular cells of the liver, but nitrotyrosine‐protein adducts in the same cells, the site of the necrosis. Nitration of tyrosine occurs with peroxynitrite, a species formed by reaction of nitric oxide (NO·) with superoxide (O2·−).
Intracellular single‐chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells
Masato Yamamoto, Norio Hayashi, Tetsuo Takehara, Keiji Ueda, Eiji Mita, Tomohide Tatsumi, Yutaka Sasaki, Akinori Kasahara, Masatsugu Hori – 30 December 2003 – Hepatitis B virus (HBV) is one of the major causes of chronic liver diseases and hepatocellular carcinoma. In this study, we used a single chain antibody (sFv), which is a man‐made antibody with a strong affinity of immunoglobulin, to inhibit HBV replication.
Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis: A mouse model of primary biliary cirrhosis
David E. Jones, Jeremy M. Palmer, Stephen J. Yeaman, John A. Kirby, Margaret F. Bassendine – 30 December 2003 – The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by autoreactive responses to a highly conserved self‐antigen, pyruvate dehydrogenase complex (PDC). We recently reported the development of PBC‐like lesions in SJL mice sensitized with PDC and have named this model disease experimental autoimmune cholangitis (EAC). In the present study, the breakdown of tolerance to PDC has been investigated in animals sensitized for EAC.
Primary biliary cirrhosis once rare, now common in the United Kingdom?
Oliver F. James, Raj Bhopal, Denise Howel, Jackie Gray, Alastair D. Burt, Jane V. Metcalf – 30 December 2003 – There is a widespread impression that the number of patients with the autoimmune liver disease primary biliary cirrhosis (PBC) is increasing, although its incidence and prevalence vary widely.
Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2
Toshinori Kamisako, Inka Leier, Yunhai Cui, Jörg König, Ulrike Buchholz, Johanna Hummel‐Eisenbeiss, Dietrich Keppler – 30 December 2003 – The secretion of bilirubin conjugates from hepatocytes into bile represents a decisive step in the prevention of hyperbilirubinemia.
Anomalous development of the hepatobiliary system in the inv mouse
Mark V. Mazziotti, Lauren K. Willis, Robert O. Heuckeroth, Marie C. LaRegina, Paul E. Swanson, Paul A. Overbeek, David H. Perlmutter – 30 December 2003 – Extrahepatic biliary atresia (BA) is a devastating disease of the neonate in which the hepatic and/or common bile duct is obliterated or interrupted. Infants and children with this diagnosis constitute 50% to 60% of the pediatric population that undergoes orthotopic liver transplantation. However, there is still very little known about the etiology and pathogenesis of BA.
Immune response in chronic hepatitis C–infected patients undergoing interferon treatment
Antonietta Cargnel, Guido Gubertini, Carlo Magnani, Simona Bosis, Fulvia Colombo, Mario Clerici – 30 December 2003
Congenital hepatic fibrosis—Is it really a matter of “a spoonful of sugar?”
Sarah Jane Schwarzenberg – 30 December 2003
Current practice patterns of primary care physicians in the management of patients with hepatitis C
Thomas M. Shehab, Seema S. Sonnad, Mark Jeffries, Naresh Gunaratnum, Anna S. Lok – 30 December 2003 – Approximately 4 million Americans are infected with the hepatitis C virus (HCV). Most patients with hepatitis C have no symptoms until cirrhosis is established. Thus, initial diagnosis and management of hepatitis C rely on primary care physicians identifying and screening high‐risk individuals.